A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.

Szczegóły
Abstrakt

Tytuł:: A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
Autorzy:: Medina-Catalán D; Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, 08041, Barcelona, Spain.
Riera P; Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, 08041, Barcelona, Spain.; U705, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Barcelona, Spain.
Pagès-Puigdemont N; Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, 08041, Barcelona, Spain. .
Masip M; Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, 08041, Barcelona, Spain.
López-Ferrer A; Dermatology Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Vilarrasa E; Dermatology Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Puig L; Dermatology Department, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Źródło:: International journal of clinical pharmacy [Int J Clin Pharm] 2022 Jun; Vol. 44 (3), pp. 725-730. Date of Electronic Publication: 2022 Apr 05.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Dordrecht : Springer
MeSH Terms:: Antibodies, Monoclonal*/adverse effects
Psoriasis*/diagnosis
Psoriasis*/drug therapy
Antibodies, Monoclonal, Humanized ; Biological Therapy ; Cohort Studies ; Humans ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome
References:: Parisi R, Symmons DP, Griffiths CE, et al. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85. (PMID: 10.1038/jid.2012.339)
Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72. (PMID: 10.1016/j.jaad.2018.11.057)
Kwan Z, Bong YB, Tan LL, et al. Determinants of quality of life and psychological status in adults with psoriasis. Arch Dermatol Res. 2018;310(5):443–51. (PMID: 10.1007/s00403-018-1832-x)
Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018;201(6):1605–13. (PMID: 10.4049/jimmunol.1800013)
Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616–26. (PMID: 10.1111/jdv.14433)
Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–86. (PMID: 10.1016/j.jaad.2020.02.044)
Bai F, Li GG, Liu Q, et al. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Immunol Res. 2019;2019:2546161. (PMID: 10.1155/2019/2546161)
Armstrong AW, Puig L, Joshi A, et al. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020;156(3):258–69. (PMID: 10.1001/jamadermatol.2019.4029)
European Medicines Agency. Guselkumab (Tremfya) drug label [Internet]. Available in: https://www.ema.europa.eu/en . Accessed 25.08.2021.
Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17. (PMID: 10.1016/j.jaad.2016.11.041)
Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–31. (PMID: 10.1016/j.jaad.2016.11.042)
Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936–45. (PMID: 10.1016/j.jaad.2019.11.040)
Armstrong AW, Reich K, Foley P, et al. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. Am J Clin Dermatol. 2019;20(1):155–64. (PMID: 10.1007/s40257-018-0396-z)
Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–9. (PMID: 10.1016/S0140-6736(19)31773-8)
Rodriguez Fernandez-Freire L, Galán-Gutierrez M, Armario-Hita JC, et al. Guselkumab: Short-term effectiveness and safety in real clinical practice. Dermatol Ther. 2020;33(3):e13344. (PMID: 10.1111/dth.13344)
Benhadou F, Ghislain PD, Guiot F, et al. Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020;34(12):e837–9. (PMID: 10.1111/jdv.16715)
Megna M, Fabbrocini G, Cinelli E, et al. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J Dermatolog Treat. 2020;1-5.
Fougerousse AC, Ghislain PD, Reguiai Z, et al. Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study. J Eur Acad Dermatol Venereol. 2020;34(10):e644–6. (PMID: 10.1111/jdv.16511)
Maliyar K, O'Toole A, Gooderham MJ. Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab. J Cutan Med Surg. 2020;24(6):588–95. (PMID: 10.1177/1203475420932514)
Galluzzo M, Tofani L, Lombardo P, et al. Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study. J Clin Med. 2020;9(7):2170. (PMID: 10.3390/jcm9072170)
Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, et al. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther. 2021:e14798.
Snast I, Sherman S, Holzman R, et al. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6):e13964. (PMID: 10.1111/dth.13964)
Schwensen JFB, Nielsen VW, Nissen CV, et al. Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study. J Eur Acad Dermatol Venereol. 2021;35(5):e341–3. (PMID: 10.1111/jdv.17092)
Ruggiero A, Fabbrocini G, Cinelli E, et al. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study. Dermatol Ther. 2021;34(1):e14673. (PMID: 33314658)
Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical Reactions to Biologic Therapy in Psoriasis: A Review of the Literature. Actas Dermosifiliogr. 2018;109(9):791–800. (PMID: 10.1016/j.ad.2018.04.003)
Contributed Indexing:: Keywords: Biologic; effectiveness; guselkumab; psoriasis; real-life; refractory
Substance Nomenclature:: 0 (Antibodies, Monoclonal)
0 (Antibodies, Monoclonal, Humanized)
089658A12D (guselkumab)
Entry Date(s):: Date Created: 20220405 Date Completed: 20220617 Latest Revision: 20220617
Update Code:: 20240105
DOI:: 10.1007/s11096-022-01400-z
PMID:: 35380392
: Czasopismo naukowe

Full Text Finder

Background Guselkumab is indicated for moderate-to-severe plaque psoriasis. Data from real-life clinical practice regarding its use are scarce, especially concerning patients who relapse after previous biologic therapies. Aim This study aimed to evaluate the effectiveness, safety, and adherence to guselkumab in psoriasis refractory to biologic therapies. Method This real-life, retrospective study included patients who initiated guselkumab between February 2019 and October 2020. The main objective was to assess effectiveness, expressed as the psoriasis area and severity index (PASI) ≤5, ≤2 and 0, at the first follow-up medical visit. As secondary effectiveness outcomes, we assessed the body surface area (BSA) and dermatology life quality index (DLQI). We also evaluated adverse events and adherence (using the medication possession ratio [MPR]). Results The study included 35 patients who had previously received a median of two biologic drugs. The median basal PASI score (IQR) was 11 (7.3-15.9), decreasing to 0 (0-1.4) at first follow-up medical visit. At this point, 32 patients (94.1%) reached PASI ≤5, 28 (82.4%) PASI ≤2 and 19 (55.9%) PASI 0. We also found statistically significant improvements in PASI, BSA and DLQI at first follow-up (p<0.001). Three patients developed adverse events. Most patients (N=29, 85.3%) had an MPR ≥90%. The MPR was not associated with PASI score at first follow-up. Conclusion Our study supports evidence that guselkumab is an effective and safe drug in psoriasis refractory to biologic therapies. Adherence to treatment is not related to effectiveness, suggesting that, in some cases, the interval between doses could be increased.
(© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)

Informacja